Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients.
Kimberley Allen-PhilbeyStefania De TraneZhifeng MaoCesar Álvarez-GonzálezJoela MathewsAmy MacDougallAndrea StennettXia ZhouOzlem YildizAshok AdamsLucia BianchiCamilla BlainChristine ChapmanKaren ChungCris S ConstantinescuCatherine DaltonRachel A FarrellLeonora FisnikuHelen FordBruno GranJeremy HobartZhaleh KhaleeliMiriam MattoscioSue PavittOwen PearsonLuca Peruzzotti-JamettiAntonio ScalfariBasil SharrackEli SilberEmma C TallantyreStewart WebbBenjamin P TurnerMonica MartaSharmilee GnanapavanGunnar JuliussonGavin GiovannoniDavid BakerKlaus SchmiererPublished in: Therapeutic advances in neurological disorders (2021)
was well tolerated. Effectiveness in relapsing MS appeared similar to cladribine tablets and was encouraging in progressive MS. Our data suggest cladribine may be safe and effective in MS-patients irrespective of their disease stage.
Keyphrases
- multiple sclerosis
- end stage renal disease
- ejection fraction
- mass spectrometry
- chronic kidney disease
- newly diagnosed
- ms ms
- prognostic factors
- randomized controlled trial
- systematic review
- white matter
- rheumatoid arthritis
- machine learning
- patient reported outcomes
- artificial intelligence
- deep learning
- patient reported